NZ510359A - Amelioration of apomorphine adverse effects for sexual dysfunction in males and females - Google Patents

Amelioration of apomorphine adverse effects for sexual dysfunction in males and females

Info

Publication number
NZ510359A
NZ510359A NZ510359A NZ51035999A NZ510359A NZ 510359 A NZ510359 A NZ 510359A NZ 510359 A NZ510359 A NZ 510359A NZ 51035999 A NZ51035999 A NZ 51035999A NZ 510359 A NZ510359 A NZ 510359A
Authority
NZ
New Zealand
Prior art keywords
apomorphine
patient
dose
adverse effects
sexual dysfunction
Prior art date
Application number
NZ510359A
Other languages
English (en)
Inventor
Ragab El-Rashidy
Bruce Ronsen
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Publication of NZ510359A publication Critical patent/NZ510359A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ510359A 1998-08-24 1999-07-01 Amelioration of apomorphine adverse effects for sexual dysfunction in males and females NZ510359A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/138,982 US5994363A (en) 1998-08-24 1998-08-24 Amelioration of apomorphine adverse effects
PCT/US1999/014965 WO2000010567A1 (en) 1998-08-24 1999-07-01 Amelioration of apomorphine adverse effects

Publications (1)

Publication Number Publication Date
NZ510359A true NZ510359A (en) 2003-06-30

Family

ID=22484576

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ510359A NZ510359A (en) 1998-08-24 1999-07-01 Amelioration of apomorphine adverse effects for sexual dysfunction in males and females

Country Status (14)

Country Link
US (1) US5994363A (enExample)
EP (1) EP1105129A4 (enExample)
JP (1) JP2002523370A (enExample)
CN (1) CN1212841C (enExample)
AU (1) AU764068B2 (enExample)
BR (1) BR9913235A (enExample)
CA (1) CA2341673A1 (enExample)
CZ (1) CZ2001610A3 (enExample)
HU (1) HUP0201212A3 (enExample)
IL (1) IL141512A0 (enExample)
NO (1) NO20010899L (enExample)
NZ (1) NZ510359A (enExample)
PL (1) PL346273A1 (enExample)
WO (1) WO2000010567A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
IL151614A0 (en) 2000-04-07 2003-04-10 Tap Holdings Inc Apomorphine derivatives and methods for their use
EP1284653B1 (en) * 2000-05-09 2007-11-28 Nitromed, Inc. Infrared thermography and treatment of sexual dysfunctions
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
WO2002062315A1 (en) * 2001-02-08 2002-08-15 Pharmacia Corporation Rapid-onset medicament for the treatment of sexual dysfunction
ES2180446B1 (es) * 2001-07-02 2004-01-16 Esteve Labor Dr Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.
KR100666520B1 (ko) * 2002-02-07 2007-01-11 파마시아 코포레이션 점막 송달을 위한 약제학적 투약형
EP1496915A1 (en) * 2002-03-19 2005-01-19 Brain 'N' Beyond Biotech Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
NZ536965A (en) * 2002-05-31 2007-02-23 Titan Pharmaceuticals Inc Nonerodible polymeric matrix with buprenorphine encapsulated for the treatment of opiate addiction and pain
AU2003284005B2 (en) * 2002-10-03 2009-12-17 Forest Laboratories Holdings Limited Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
MXPA05010450A (es) 2003-03-31 2005-11-04 Titan Pharmaceuticals Inc Dispositivo polimerico implantable para la liberacion prolongada de agonistas de dopamina.
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
AU2004228757A1 (en) * 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
CA2562465A1 (en) * 2004-04-13 2005-10-27 The Mclean Hospital Corporation R(-)-11-hydroxyaporphine derivatives and uses thereof
US20060083724A1 (en) * 2004-10-01 2006-04-20 Hilst Todd W Compositions for the treatment of femal sexual dysfunction
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
WO2009003147A1 (en) * 2007-06-26 2008-12-31 Parkinson's Institute Methods and compositions for the treatment of neurological disorders
US8431591B2 (en) * 2007-07-12 2013-04-30 The Mclean Hospital Corporation R(−)-2-methoxy-11-hydroxyaporphine and derivatives thereof
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
PL2952191T3 (pl) 2009-06-12 2019-02-28 Sunovion Pharmaceuticals Inc. Apomorfina w postaci do podawania podjęzykowego
CN103476372B (zh) 2010-12-16 2016-04-27 Cynapsus疗法有限公司 舌下薄膜
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
ES3015535T3 (en) 2015-04-21 2025-05-06 Sumitomo Pharma America Inc Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
IT202100009857A1 (it) 2021-04-19 2022-10-19 Univ Degli Studi Di Torino Formulazione a rilascio controllato e prolungato di apomorfina

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) * 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US3976780A (en) * 1968-07-29 1976-08-24 Societe D'etudes Scientifiques Et Industrielles L'ile-De-France Methods of protection against emesis in mammals by administration of a 3-alkoxy-thianaphthene-2-carboxamide
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
AU1508183A (en) * 1982-06-04 1983-12-08 Beecham Group Plc Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane
US4687773A (en) * 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4624965A (en) * 1984-11-15 1986-11-25 Nastech Pharmaceutical Co., Inc. Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same
US4749700A (en) * 1984-10-23 1988-06-07 Nastech Pharmaceutical Co, Inc. Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
US4772459A (en) * 1986-09-09 1988-09-20 Erbamont, Inc. Method for controlling emesis caused by chemotherapeutic agents and antiemetic agents useful therein
US4749686A (en) * 1986-12-04 1988-06-07 New York Medical College Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5102887A (en) * 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
DE69514794T2 (de) * 1994-04-22 2000-07-27 Pentech Pharmaceuticals, Inc. Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine

Also Published As

Publication number Publication date
US5994363A (en) 1999-11-30
CN1324238A (zh) 2001-11-28
AU4965199A (en) 2000-03-14
BR9913235A (pt) 2001-12-04
CZ2001610A3 (cs) 2002-03-13
CN1212841C (zh) 2005-08-03
HUP0201212A2 (en) 2002-08-28
CA2341673A1 (en) 2000-03-02
IL141512A0 (en) 2002-03-10
HUP0201212A3 (en) 2004-12-28
AU764068B2 (en) 2003-08-07
NO20010899D0 (no) 2001-02-22
PL346273A1 (en) 2002-01-28
EP1105129A4 (en) 2003-11-12
JP2002523370A (ja) 2002-07-30
NO20010899L (no) 2001-04-24
WO2000010567A1 (en) 2000-03-02
EP1105129A1 (en) 2001-06-13

Similar Documents

Publication Publication Date Title
NZ510359A (en) Amelioration of apomorphine adverse effects for sexual dysfunction in males and females
JO2085B1 (en) Addressing sexual dysfunction for women
US5891915A (en) Method for enhancing female sexual response and an ointment therefor
KR970702041A (ko) 남성 발기 기능장애를 회복시키기 위한 용량형 및 이를 위한 방법(Dosage forms and method for ameliorating male erectile dysfunction)
EA200001044A2 (ru) Соединения для лечения женской сексуальной дисфункции
AU6848098A (en) Use of misoprostol or/and misoprostol acid for preparing drug in order to cu re erectile dysfunction
HUP9902094A2 (hu) PGE-1-tartalmú liofilizált liposzómák erekciós zavar kezelésében való alkalmazásra
Steinberger The treatment of dysmenorrhea by acupuncture
GB0208704D0 (en) Condom
AR019694A1 (es) Metodo para el tratamiento o reduccion de la disfuncion sexual femenina.
AU2001236529A1 (en) Combination therapy for cancer
Wang Electroacupuncture pudendal nerve stimulation and its application
CN2229257Y (zh) 一种理疗球
CN201175401Y (zh) 物理延时型安全套
CN201384597Y (zh) 一种延时衬垫
RU2266095C2 (ru) Способ лечения сексуальных нарушений у мужчин
Newell A case of ejaculatory incompetence treated with a mechanical aid
CN2139442Y (zh) 妇女性欲冷淡治疗器
Leyson in Female Sexuality
Fishman et al. Case report, lontophoretic delivery of steroids in the treatment of Peyronie's disease: Case reports of three successful outcomes
CN1116888C (zh) 治疗女性性功能疾病的药物组合物
Hongzhao et al. Acupuncture treatment for insomnia
KR20130119704A (ko) 기능성 팬티
KR20220109191A (ko) 음경 보조기구
CN2101475U (zh) 医用壮阳带

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)